Statins for primary prevention of cardiovascular disease in Germany: benefits and costs
Lowering the threshold for statin therapy to a risk of 7.5 percent of either non-fatal myocardial infarction, coronary heart disease death, non-fatal or fatal stroke would align statin prescription in Germany with international standards. There is no urgent rationale for applying age-stratified risk thresholds.
Authors
- Winfried März (ORCID: https://orcid.org/0000-0001-6083-8946)
- Felix Fath
- Alexander Dressel (ORCID: https://orcid.org/0000-0002-7630-7223)
- Bernhard K. Krämer
- Gerald Klose
Institutions
- Medical University of Graz (AT)
- Heidelberg University (DE)
- University Hospital Heidelberg (DE)
- NXP (Germany) (DE)
- Synlab (Germany) (DE)
- University Medical Centre Mannheim (DE)
Publication Details
- Journal
- Clinical Research in Cardiology
- Published
- 2025-03-17
- DOI
- https://doi.org/10.1007/s00392-025-02608-5
- Citations
- 1
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 2.01